These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 28884752)

  • 21. Cerebral white matter lesions are not associated with apoE genotype but with age and female sex in Alzheimer's disease.
    Sawada H; Udaka F; Izumi Y; Nishinaka K; Kawakami H; Nakamura S; Kameyama M
    J Neurol Neurosurg Psychiatry; 2000 May; 68(5):653-6. PubMed ID: 10766901
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of APOE genotype on clinical phenotype in Alzheimer disease.
    van der Flier WM; Schoonenboom SN; Pijnenburg YA; Fox NC; Scheltens P
    Neurology; 2006 Aug; 67(3):526-7. PubMed ID: 16894123
    [TBL] [Abstract][Full Text] [Related]  

  • 23. APOE genotype effects on Alzheimer's disease onset and epidemiology.
    Ashford JW
    J Mol Neurosci; 2004; 23(3):157-65. PubMed ID: 15181244
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The Alzheimer-apoE4 connection].
    Jørgensen AL
    Ugeskr Laeger; 1993 Nov; 155(48):3936-7. PubMed ID: 8273205
    [No Abstract]   [Full Text] [Related]  

  • 25. White matter lesions in Alzheimer patients are influenced by apolipoprotein E genotype.
    Bronge L; Fernaeus SE; Blomberg M; Ingelson M; Lannfelt L; Isberg B; Wahlund LO
    Dement Geriatr Cogn Disord; 1999; 10(2):89-96. PubMed ID: 10026381
    [TBL] [Abstract][Full Text] [Related]  

  • 26. APOE genotype and gender effects on Alzheimer disease in 100 adults with Down syndrome.
    Lai F; Kammann E; Rebeck GW; Anderson A; Chen Y; Nixon RA
    Neurology; 1999 Jul; 53(2):331-6. PubMed ID: 10430422
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Apolipoprotein E epsilon 4 is a determinant for Alzheimer-type pathologic features in tauopathies, synucleinopathies, and frontotemporal degeneration.
    Josephs KA; Tsuboi Y; Cookson N; Watt H; Dickson DW
    Arch Neurol; 2004 Oct; 61(10):1579-84. PubMed ID: 15477512
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Apolipoprotein E affects the rate of Alzheimer disease expression: beta-amyloid burden is a secondary consequence dependent on APOE genotype and duration of disease.
    Roses AD
    J Neuropathol Exp Neurol; 1994 Sep; 53(5):429-37. PubMed ID: 8083686
    [No Abstract]   [Full Text] [Related]  

  • 29. Protective effect of apo epsilon 2 in Alzheimer's disease. Oxford Project to Investigate Memory and Ageing (OPTIMA).
    Smith AD; Johnston C; Sim E; Nagy Z; Jobst KA; Hindley N; King E
    Lancet; 1994 Aug; 344(8920):473-4. PubMed ID: 7914581
    [No Abstract]   [Full Text] [Related]  

  • 30. [The apolipoprotein E gene and Alzheimer disease phenotype].
    Kurz A; Egensperger R; Lautenschlager N; Haupt M; Altland K; Graeber MB; Müller U
    Z Gerontol Geriatr; 1995; 28(3):195-9. PubMed ID: 7664194
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Alzheimer dementia--a disorder of lipoprotein metabolism?].
    Miserez AR
    Praxis (Bern 1994); 2001 Aug; 90(31-32):1297-9. PubMed ID: 11523536
    [No Abstract]   [Full Text] [Related]  

  • 32. Alzheimer's disease, apolipoprotein E4, and gender.
    Payami H; Montee KR; Kaye JA; Bird TD; Yu CE; Wijsman EM; Schellenberg GD
    JAMA; 1994 May; 271(17):1316-7. PubMed ID: 8158809
    [No Abstract]   [Full Text] [Related]  

  • 33. No increased risk of the apolipoprotein E epsilon2 allele with early-onset Alzheimer's disease.
    Corder EH; Roses AD
    Ann Neurol; 1996 Mar; 39(3):414-6. PubMed ID: 8602768
    [No Abstract]   [Full Text] [Related]  

  • 34. Sex differences in the clinical manifestations of Alzheimer disease pathology.
    Barnes LL; Wilson RS; Bienias JL; Schneider JA; Evans DA; Bennett DA
    Arch Gen Psychiatry; 2005 Jun; 62(6):685-91. PubMed ID: 15939846
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relationship of vascular risk to the progression of Alzheimer disease.
    Borroni B; Archetti S; Ferrari M; Cesana BM; Padovani A
    Neurology; 2007 Mar; 68(13):1083-4; author reply 1084. PubMed ID: 17389321
    [No Abstract]   [Full Text] [Related]  

  • 36. [Apolipoprotein E and Alzheimer's disease].
    Lahoz C; Ordovás JM
    Rev Clin Esp; 1997 Feb; 197(2):73-4. PubMed ID: 9213859
    [No Abstract]   [Full Text] [Related]  

  • 37. Apolipoprotein E genotype: utility in clinical practice in Alzheimer's disease.
    Hyman BT
    J Am Geriatr Soc; 1996 Dec; 44(12):1469-71. PubMed ID: 8951318
    [No Abstract]   [Full Text] [Related]  

  • 38. Smoking and risk of Alzheimer's disease.
    Asada T; Yamagata Z; Motonaga T; Kimura M; Uno M
    Lancet; 1998 Sep; 352(9130):818-9. PubMed ID: 9737314
    [No Abstract]   [Full Text] [Related]  

  • 39. [Apolipoprotein E and Alzheimer's disease].
    Creveaux I; Dastugue B
    Ann Biol Clin (Paris); 1998; 56(2):130-1. PubMed ID: 9754236
    [No Abstract]   [Full Text] [Related]  

  • 40. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease.
    Corder EH; Saunders AM; Risch NJ; Strittmatter WJ; Schmechel DE; Gaskell PC; Rimmler JB; Locke PA; Conneally PM; Schmader KE
    Nat Genet; 1994 Jun; 7(2):180-4. PubMed ID: 7920638
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.